Compare Cronos Group Inc (CRON) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs US Bancorp — how do they compare? Cronos Group Inc trades at $3.08 (market cap $1.11B), while US Bancorp trades at $64.51 (market cap $100.01B). The key difference: US Bancorp is far larger — about 90.1× Cronos Group Inc's market cap, and US Bancorp pays a 3.24% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CRON | USB | |
|---|---|---|
Market Cap | $1.11B | $100.01B |
Sector | Health | Financials |
52-Week High | $3.27 | $64.47 |
52-Week Low | $2.30 | $45.28 |
Enterprise Value | $310.67M | — |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.10 with a 0.98% daily gain, showing bullish technical momentum. The company delivered strong Q2 2026 results with 58% YoY revenue growth and earnings beat, while maintaining #1 market share in Canadian vapes and edibles. Despite negative net income in 2025, revenue growth accelerated to $147M with improving margins. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near $3 resistance.
Outlook remains positive with international expansion and European cannabis legalization driving growth, though competitive pressures and execution risks persist. Analyst consensus is mixed with 60% hold ratings, reflecting cautious optimism about CRON's turnaround trajectory from previous losses to projected 39% profit margin by 2026.
U.S. Bancorp (USB) trades at $63.94, up 0.2% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $70.27. The stock shows strong fundamentals with a P/E of 12.76, net income margin of 27.61%, and three consecutive quarterly EPS beats. Recent news highlights institutional buying and upbeat Q2 2026 results, though RSI levels suggest potential overbought conditions near-term.
Outlook is positive with earnings growth and dividend stability, but risks include interest rate sensitivity and competitive pressures. Upside potential exists if the company maintains its profit trajectory, supported by analyst buy ratings. Investors should monitor debt levels and economic shifts that could impact banking sector performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
